Clinical trial with BugSpeaks, gut microbiome profiling kit, shows improved blood glucose

The study included Indians in the age range of 42-65 years with hyperglycaemia and hyperlipidemia

A first-of-its-kind clinical trial in India shows remarkable results for people with diabetes. The trial was conducted using BugSpeaks, a flagship technology of Leucine Rich Bio, India’s first microbiome-based company. BugSpeaks is a gut microbiome profiling test that provides nutritional recommendations based on the individual’s gut microbiota profile. With India being called the diabetes capital of the world housing more than 101 million people with diabetes, the results of this study are groundbreaking for the prevention and management of diabetes. 

The clinical trial included 30 Indian adults in the age group 42-65, both male and female, with hyperglycemia (high blood sugar) and hyperlipidaemia (high cholesterol). Study subjects were divided into two groups: one received the BugSpeaks-based personalized diet and the other a regular diet for 3 months. The patients who were given a BugSpeaks-based personalized diet showed excellent results across various parameters when examined on day 90 of the study. Their HbA1c levels were brought down from 8.30 to 6.67, systolic blood pressure was reduced by 14 per cent, and CRP levels, a marker of inflammation, were decreased by 20 per cent. The study has been uploaded onto a preprint server MedRxiv and is yet to undergo peer review.

Read Previous

Diageo launches open innovation call to improve water use across supply chain

Read Next

NCCF launches Bharat brand of pulses at subsidised prices in Tamil Nadu

Leave a Reply